ArticleInvestigational new drugs2019

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer.

Alexandra Leary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.